MRI as a Novel In Vivo Approach for Assessing Structural Changes of Chlamydia Pathology in a Mouse Model

• Catherine D. G. Hines ,

  * E-mail: catherine.hines@merck.com

  Affiliation Department of Translational Imaging Biomarkers, MRL (West Point, PA), Merck & Co., Inc., Kenilworth, New Jersey, United States of America

  http://orcid.org/0000-0001-9826-3164

  ⨯
• Shubing Wang,

  Affiliation Department of Biometrics Research, MRL (Rahway, NJ), Merck & Co., Inc., Kenilworth, New Jersey, United States of America

  ⨯
• Xiangjun Meng,

  Affiliation Department of Translational Imaging Biomarkers, MRL (West Point, PA), Merck & Co., Inc., Kenilworth, New Jersey, United States of America

  ⨯
• Julie M. Skinner,

  Affiliation Department of Vaccines Early Discovery, MRL (West Point, PA), Merck & Co., Inc., Kenilworth, New Jersey, United States of America

  ⨯
• Jon H. Heinrichs,

  Affiliation Global Project Leadership, Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America

  ⨯
• Jeffrey G. Smith,

  Affiliation Pharmaceutical Sciences Analytical Research & Development, Pfizer, Andover, Massachusetts, United States of America

  ⨯
• Melissa A. Boddicker

  Affiliation Department of Vaccines Early Discovery, MRL (West Point, PA), Merck & Co., Inc., Kenilworth, New Jersey, United States of America

  ⨯